Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM
Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.
EP: 1.How Uveal Melanoma Differs from Cutaneous Melanoma
EP: 2.Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient
EP: 3.Historic and Current Treatment Options for mUM
Now Viewing
EP: 4.Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM
EP: 5.Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
EP: 6.An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources
EP: 7.Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy
EP: 8.Advice for Patients Living with Metastatic Uveal Melanoma
Related Videos
Related Content
